作者
Yilong Wang, Weiqi Chen, Yi Lin, Xia Meng, Guohua Chen, Zhimin Wang, Jialing Wu, Dali Wang, Jianhua Li, Yibin Cao, Yuming Xu, Guohua Zhang, Xiaobo Li, Yuesong Pan, Hao Li, Xingquan Zhao, Liping Liu, Jinxi Lin, Kehui Dong, Jing Jing, S Claiborne Johnston, David Wang, Yongjun Wang
发表日期
2019/6/6
期刊
bmj
卷号
365
出版商
British Medical Journal Publishing Group
简介
Objective
To test the hypothesis that ticagrelor plus aspirin is safe and superior to clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence in patients with minor stroke or transient ischaemic attack, particularly in carriers of the CYP2C19 loss-of-function allele and patients with large artery atherosclerosis.
Design
Open label, blinded endpoint, randomised controlled phase II trial.
Setting
Prospective studies conducted at 26 centres in China, August 2015 to March 2017.
Participants
675 patients with acute minor stroke or transient ischaemic attack.
Intervention
Ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300 mg loading dose, 75 mg daily thereafter) on a background of aspirin (100 mg daily for the first 21 days) within 24 hours of symptom onset.
Main outcome measures
Primary outcome was the proportion of patients with high platelet reactivity at 90 …
学术搜索中的文章
Y Wang, W Chen, Y Lin, X Meng, G Chen, Z Wang… - bmj, 2019